Plant compound targets rheumatoid arthritis at molecular level in preclinical study

Rheumatoid arthritis is a disease of mistaken identity. The immune system turns on the body's own joints, causing pain, swelling, and progressive damage that affects roughly one in every hundred people worldwide. Existing treatments help some patients but not others, and the side effects can be severe. Now researchers have found that a compound derived from plants—obakulactone, or OL—can reduce joint damage and inflammation in rats by working at a molecular level that previous approaches have largely overlooked.

In the laboratory, scientists gave rats with arthritis three different doses of obakulactone over three weeks. The results were consistent across all dose levels: joint swelling decreased, cartilage structure improved, and the synovium—the tissue lining the inside of joints—began to heal. The compound also restored the normal appearance of immune organs like the thymus and spleen, which had been damaged by the disease. Blood tests revealed that obakulactone lowered multiple inflammatory molecules: IL-1β, IL-6, IL-17, and TNF-α all dropped in a dose-dependent pattern. Standard markers used to diagnose rheumatoid arthritis—rheumatoid factor, anti-CCP antibodies, C-reactive protein, and MMP-3—also declined.

What made this finding unusual was not just that the compound worked, but how it worked. Using advanced analytical techniques including metabolomics and mass spectrometry imaging, researchers discovered that rheumatoid arthritis had disrupted the body's normal production and processing of unsaturated fatty acids. Obakulactone helped restore these disrupted pathways, correcting abnormalities in arachidonic acid, linoleic acid, and α-linolenic acid metabolism. The compound also shifted the behavior of immune cells. It reduced the number of T cells and macrophages flooding into the joints, and it pushed macrophages away from their pro-inflammatory state toward an anti-inflammatory one. It also prevented T cells from developing into Th17 cells, which promote inflammation.

The mechanism became clearer through a series of precise experiments. Researchers showed that obakulactone binds directly to a protein called ACOT1. When the compound attaches to this protein, it triggers the cell to tag ACOT1 with molecular markers and send it to the proteasome—the cellular machinery that breaks down unwanted proteins. With less ACOT1 present, a downstream protein called SCD1 also decreased. This, in turn, dampened two major signaling pathways: JAK-STAT and PI3K-AKT. These pathways normally help regulate cell survival, growth, inflammation, and fibrosis. By suppressing them, obakulactone reduced both inflammatory and fibrotic changes in synovial fibroblasts—the cells that grow excessively in rheumatoid arthritis and contribute to joint damage.

The researchers also tested obakulactone directly on synovial fibroblasts in the laboratory. The compound slowed their abnormal growth, pushed them toward cell death, and reduced their release of inflammatory molecules. Additional experiments using inhibitors and rescue techniques confirmed that obakulactone produced its effects specifically by targeting ACOT1 and influencing the fatty acid and signaling pathways downstream.

These findings identify two new targets for drug development: ACOT1 itself and the disrupted fatty acid metabolism that characterizes rheumatoid arthritis. The work is still preclinical—conducted in rats and isolated cells—so the critical next step is determining whether obakulactone is safe and effective in humans. But the molecular pathway is now clear, and the compound's effects are reproducible across multiple measures of disease and inflammation. For patients who do not respond well to current treatments, or who suffer their side effects, a new approach targeting fatty acid metabolism could eventually offer another option.